Hormone therapy is a broad and impactful area of pharmacotherapy, encompassing treatments from contraception to the management of menopausal symptoms. Its use requires a careful, individualized assessment of risks and benefits, a core competency taught to pharmacists in the “Women’s Health” module of the Patient Care 5 curriculum. This quiz will test your knowledge of the principles, indications, Therapy
1. What is the primary indication for systemic menopausal hormone therapy (MHT)
- a. Primary prevention of cardiovascular disease.
- b. Treatment of moderate-to-severe vasomotor symptoms (hot flashes).
- c. First-line treatment for osteoporosis in all women.
- d. Weight loss.
Answer: b. Treatment of moderate-to-severe vasomotor symptoms (hot flashes).
2. In a woman with an intact uterus, why must a progestin be given with estrogen for menopausal hormone therapy?
- a. To increase the effectiveness of estrogen for hot flashes.
- b. To oppose estrogen’s effect on the endometrium and reduce the risk of endometrial cancer.
- c. To improve bone mineral density.
- d. To lower the risk of venous thromboembolism (VTE).
Answer: b. To oppose estrogen’s effect on the endometrium and reduce the risk of endometrial cancer.
3. According to the “timing hypothesis,” the risk-benefit profile for MHT is most favorable for women who:
- a. Are older than 70 years.
- b. Are more than 10 years past the onset of menopause.
- c. Are aged <60 years and within 10 years of menopause onset.
- d. Have a history of breast cancer.
Answer: c. Are aged <60 years and within 10 years of menopause onset.
4. Which route of estrogen administration is thought to have a lower risk of venous thromboembolism (VTE) compared to the oral route?
- a. Intramuscular
- b. Sublingual
- c. Transdermal
- d. Oral is the safest route.
Answer: c. Transdermal
5. The primary mechanism by which combined hormonal contraceptives prevent pregnancy is:
- a. Thickening cervical mucus only.
- b. Suppression of ovulation.
- c. Creating a physical barrier.
- d. Acting as a spermicide.
Answer: b. Suppression of ovulation.
6. The “Women’s Health” module, which covers hormone therapy, is a specific learning module in which course?
- a. PHA5787C Patient Care 5
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5878C Patient Care 3
Answer: a. PHA5787C Patient Care 5
7. A woman who has had a hysterectomy and requires MHT can be treated with:
- a. Estrogen-only therapy.
- b. Progestin-only therapy.
- c. Estrogen plus progestin therapy.
- d. A selective estrogen receptor modulator (SERM).
Answer: a. Estrogen-only therapy.
8. Which of the following is an absolute contraindication to starting menopausal hormone therapy?
- a. A history of urinary tract infections.
- b. A history of estrogen-sensitive breast cancer.
- c. Controlled hypertension.
- d. A family history of osteoporosis.
Answer: b. A history of estrogen-sensitive breast cancer.
9. For a woman experiencing only genitourinary syndrome of menopause (GSM), such as vaginal dryness, the preferred therapy is:
- a. A high-dose systemic estrogen patch.
- b. A low-dose, local vaginal estrogen product.
- c. An oral progestin-only pill.
- d. A systemic SERM like raloxifene.
Answer: b. A low-dose, local vaginal estrogen product.
10. What is the key difference between progesterone and a progestin?
- a. There is no difference.
- b. Progesterone is synthetic, and a progestin is natural.
- c. Progesterone is the natural hormone, while a progestin is a synthetic compound with progesterone-like effects.
- d. Progestins have no side effects.
Answer: c. Progesterone is the natural hormone, while a progestin is a synthetic compound with progesterone-like effects.
11. The management of contraception and menopause are topics within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
12. The Women’s Health Initiative (WHI) trial found that combined estrogen-progestin therapy was associated with an increased risk of:
- a. Hip fractures
- b. Colorectal cancer
- c. Stroke and breast cancer
- d. Type 2 diabetes
Answer: c. Stroke and breast cancer
13. A key principle for prescribing menopausal hormone therapy is:
- a. Use the highest dose possible for the longest duration.
- b. Use the lowest effective dose for the shortest duration consistent with treatment goals.
- c. All women over 50 should be on hormone therapy.
- d. The risks are the same for all women.
Answer: b. Use the lowest effective dose for the shortest duration consistent with treatment goals.
14. A patient using a combined hormonal contraceptive patch is exposed to a higher total amount of which hormone compared to most oral pills?
- a. Progestin
- b. Estrogen
- c. Testosterone
- d. Androgen
Answer: b. Estrogen
15. Counseling patients on the appropriate use of hormonal therapies is a key objective for student pharmacists.
- a. True
- b. False
Answer: a. True
16. Which of the following is NOT a progestin-only method of contraception?
- a. The DMPA injection.
- b. The levonorgestrel IUD.
- c. The “mini-pill”.
- d. The contraceptive vaginal ring.
Answer: d. The contraceptive vaginal ring.
17. The management of osteoporosis, a condition impacted by hormones, is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
18. A non-hormonal prescription option for treating moderate-to-severe vasomotor symptoms is:
- a. A low-dose SSRI like paroxetine.
- b. A benzodiazepine.
- c. An opioid analgesic.
- d. A statin.
Answer: a. A low-dose SSRI like paroxetine.
19. Which of the following is a potential benefit of menopausal hormone therapy?
- a. Prevention of osteoporosis-related fractures.
- b. Improved glycemic control.
- c. Weight loss.
- d. Protection against STIs.
Answer: a. Prevention of osteoporosis-related fractures.
20. An active learning session on women’s health is part of the Patient Care 5 course.
- a. True
- b. False
Answer: a. True
21. “Bioidentical” hormone therapy products:
- a. Are proven to be safer and more effective than FDA-approved products.
- b. Are FDA-approved for all indications.
- c. Are often custom-compounded and have not been tested for safety or efficacy.
- d. Do not contain any hormones.
Answer: c. Are often custom-compounded and have not been tested for safety or efficacy.
22. A patient with a history of migraine with aura should avoid which type of hormone therapy?
- a. Progestin-only pills.
- b. Estrogen-containing contraceptives.
- c. Vaginal moisturizers.
- d. The copper IUD.
Answer: b. Estrogen-containing contraceptives.
23. The “Introduction to Women’s Health” lecture is part of the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
24. An active learning session on women’s health is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
25. A pharmacist’s role in hormone therapy includes:
- a. Assessing a patient’s risk factors and contraindications.
- b. Counseling on the risks and benefits of therapy.
- c. Educating on proper administration of different dosage forms (patch, ring, etc.).
- d. All of the above.
Answer: d. All of the above.
26. The term “vasomotor symptoms” refers to:
- a. Vaginal dryness and pain with intercourse.
- b. Mood swings and irritability.
- c. Hot flashes and night sweats.
- d. Bone pain and joint aches.
Answer: c. Hot flashes and night sweats.
27. Ethinyl estradiol is a potent synthetic estrogen used in most combined contraceptives.
- a. True
- b. False
Answer: a. True
28. An active learning session on women’s health is part of which course module?
- a. Module 3: Women’s Health
- b. Module 1: Diabetes Mellitus
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 3: Women’s Health
29. The decision to initiate menopausal hormone therapy should be:
- a. Made for all women at age 50.
- b. Based solely on the patient’s desire to prevent aging.
- c. An individualized decision based on a woman’s symptoms, age, and personal risk factors.
- d. Based only on the risk of breast cancer.
Answer: c. An individualized decision based on a woman’s symptoms, age, and personal risk factors.
30. The “Menopause” lecture is within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
31. A patient on a cyclic estrogen/progestin MHT regimen would expect to experience:
- a. No bleeding.
- b. Continuous spotting.
- c. Scheduled monthly withdrawal bleeding.
- d. Heavy, irregular bleeding.
Answer: c. Scheduled monthly withdrawal bleeding.
32. A major risk associated with unopposed estrogen therapy in a woman with a uterus is:
- a. Osteoporosis
- b. Endometrial cancer
- c. Vasomotor symptoms
- d. Vaginal atrophy
Answer: b. Endometrial cancer
33. Which of the following is NOT a contraindication for MHT?
- a. Undiagnosed abnormal vaginal bleeding.
- b. History of VTE.
- c. A history of hysterectomy.
- d. Active liver disease.
Answer: c. A history of hysterectomy.
34. The primary goal of hormone therapy is always to use:
- a. The highest dose possible.
- b. The newest agent available.
- c. The lowest effective dose for the shortest duration needed.
- d. An oral formulation.
Answer: c. The lowest effective dose for the shortest duration needed.
35. A pharmacist is a key resource for helping patients understand the complex risk/benefit profile of hormone therapy.
- a. True
- b. False
Answer: a. True
36. A patient taking an oral combined contraceptive who is also prescribed rifampin should be counseled about:
- a. Increased risk of VTE.
- b. The need for a backup contraceptive method due to a drug interaction.
- c. The need to increase her estrogen dose.
- d. The risk of hyperkalemia.
Answer: b. The need for a backup contraceptive method due to a drug interaction.
37. Which dosage form of estrogen avoids first-pass metabolism?
- a. Oral micronized estradiol
- b. Conjugated equine estrogens tablet
- c. Transdermal estradiol patch
- d. All oral forms.
Answer: c. Transdermal estradiol patch
38. The lecture “Contraception” is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
39. A patient wants to use a “natural” hormone therapy. A pharmacist should counsel that:
- a. “Natural” means it is safer than synthetic hormones.
- b. Custom-compounded “bioidentical” hormones are not FDA-approved and may have inconsistent potency and purity.
- c. “Bioidentical” hormones have no risks.
- d. All “natural” products are effective.
Answer: b. Custom-compounded “bioidentical” hormones are not FDA-approved and may have inconsistent potency and purity.
40. An active learning session covering women’s health is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
41. The term “hormone therapy” can apply to:
- a. Contraception
- b. Menopause management
- c. Treatment of some cancers
- d. All of the above
Answer: d. All of the above
42. Which of the following is NOT a potential side effect of estrogen therapy?
- a. Nausea
- b. Headache
- c. Breast tenderness
- d. Weight loss
Answer: d. Weight loss
43. A patient-centered approach to discussing hormone therapy involves:
- a. The pharmacist making the decision for the patient.
- b. A shared decision-making process that considers the patient’s symptoms, preferences, and risk factors.
- c. Only discussing the benefits of therapy.
- d. Only discussing the risks of therapy.
Answer: b. A shared decision-making process that considers the patient’s symptoms, preferences, and risk factors.
44. Hormonal agents for cancer are discussed in which course?
- a. Patient Care 2
- b. Patient Care 3
- c. Patient Care 4
- d. Patient Care 5
Answer: a. Patient Care 2
45. Which of the following would be an appropriate candidate for menopausal hormone therapy?
- a. A 62-year-old woman with mild hot flashes.
- b. A 51-year-old woman, 1 year post-menopause, with severe hot flashes and no contraindications.
- c. A 55-year-old woman with a history of breast cancer.
- d. A 48-year-old perimenopausal woman with a history of DVT.
Answer: b. A 51-year-old woman, 1 year post-menopause, with severe hot flashes and no contraindications.
46. A pharmacist’s role in MHT includes counseling a patient that the therapy is primarily for symptom management, not for:
- a. Relieving hot flashes.
- b. Preventing osteoporosis.
- c. Long-term prevention of chronic diseases like heart disease.
- d. Treating vaginal atrophy.
Answer: c. Long-term prevention of chronic diseases like heart disease.
47. “Hormonal Agents” is a lecture in the oncology module of Patient Care 2.
- a. True
- b. False
Answer: a. True
48. An active learning session on women’s health is part of which course module?
- a. Module 3: Women’s Health
- b. Module 1: Diabetes Mellitus
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 3: Women’s Health
49. The overall management of hormone therapy requires:
- a. A one-size-fits-all dose.
- b. Annual re-evaluation of the risks and benefits to determine if continuation is appropriate.
- c. Using the therapy for at least 10 years in all women.
- d. A focus on non-hormonal methods only.
Answer: b. Annual re-evaluation of the risks and benefits to determine if continuation is appropriate.
50. The ultimate goal of learning about hormone therapy is to:
- a. Be able to recommend the most appropriate, safe, and effective regimen based on an individual patient’s clinical presentation and goals.
- b. Memorize all the different formulations.
- c. Pass the final exam.
- d. Discourage all patients from using hormones.
Answer: a. Be able to recommend the most appropriate, safe, and effective regimen based on an individual patient’s clinical presentation and goals.
